Treatment Development & Evaluation Core

处理开发和评价核心项目摘要 数字治疗在克服获得高质量， 经验支持的治疗物质使用障碍（SUD）和共同发生的精神或身体 健康状况（COD）。数字创新可以增强现有干预措施的效力， 达到，并降低成本。使用智能手机进行行为和生理监测的数字生物标志物 以及可穿戴传感器（即，被动传感）可以提高评估过程的特异性， 提供个性化的目标，以优化干预措施。支持数字治疗的发展是 重要的是，因为大多数SUD患者没有接受SUD治疗，而那些接受治疗的人，只有一个 少数治疗是基于证据的。在过去的9年里，治疗开发和评估 (TDE)核心支持的活动，加强和加快研究的一系列技术， 改善治疗提供。我们的核心子公司的研究提高了可行性，可接受性，可用性， 创新数字健康评估工具和干预措施对多种类型SUD的有效性， 不同的人群。这些项目也提高了我们对发展的理解， 因素和SUD的变化机制。在建议的更新期内，TDE Core将继续 提高质量，效率和跨学科专家教师之间的研究项目的影响。的 核心将继续，并扩大活动，在CTBH附属公司和更大的 科学和临床社区（目标1），并提供机制，以支持加速和 科学的积累，这将提高我们对可以优化数字治疗的因素的理解， SUD和COD（目标2）。这些努力将包括5个新的CTBH优先事项（例如，数字定标 治疗，数字测量，以告知个性化的即时适应性干预（JITAI）， 整合COD和transdiagnosis机制和干预措施，数字健康伦理，并纳入 少数民族）。例如，我们会加强谘询服务， 通过扩大具有优先领域专门知识的顾问队伍， 通过开发和提供网络研讨会，完善重点并提高我们教育活动的强度， 教程和跨核心研讨会，提供关于高优先级研究目标的深入培训。核心 还将与正在进行或正在进行的数字健康项目的附属机构合作，以包括更多的研究目标， 解决我们新的优先事项。例如，在一个实施例中，增加与缩放、变化机制 或转诊断过程;包括被动传感评估，以收集数字表型数据， 与物质使用或复发有关;并评估SUD项目中的COD，以评估它们如何缓解 干预效果以及跨诊断干预如何影响结果。这些努力将加速 针对不同人群的SUD和相关病症的数字治疗科学的现状。

TREATMENT DEVELOPMENT AND EVALUATION CORE PROJECT SUMMARY Digital therapeutics hold great promise in overcoming the substantial challenges in accessing high quality, empirically supported treatments for substance use disorders (SUDs) and co-occurring mental or physical health conditions (CODs). Digital innovations can enhance the potency of existing interventions, extend their reach, and reduce costs. Digital biomarkers from behavioral and physiological monitoring using smartphones and wearable sensors (i.e., passive sensing) can improve specificity of assessment processes that in turn can provide personalized targets to optimize interventions. Supporting the development of digital therapeutics is vital, as most persons with SUDs do not receive SUD treatment, and of those who do receive treatment, only a minority of treatments are evidence-based. Over the past 9 years, the Treatment Development and Evaluation (TDE) Core has supported activities that enhance and expedite research on an array of technologies that can improve treatment delivery. Our Core affiliates’ research has advanced the feasibility, acceptability, usability, and efficacy of innovative digital health assessment tools and interventions for multiple types of SUDs among diverse populations. These projects have also improved our understanding of developmental, and maintaining factors, and mechanisms of change for SUDs. In the proposed renewal period, the TDE Core will continue to enhance the quality, efficiency, and impact of research projects among an interdisciplinary expert faculty. The Core will continue with, and expand activities for, sharing resources among CTBH affiliates and the greater scientific and clinical communities (Aim 1), and provide mechanisms to support the acceleration and accumulation of science that will enhance our understanding of factors that can optimize digital therapeutics for SUDs and CODs (Aim 2). These efforts will embrace the 5 new CTBH priorities (e.g., scaling of digital therapeutics, digital measurement to inform personalized just-in-time adaptive interventions (JITAIs), integration of CODs and transdiagnostic mechanisms and interventions, digital health ethics, and inclusion of underrepresented minority populations). For example, we will enhance our consultation services for preparing competitive grant applications by expanding the array of Advisors with expertise in the priority areas, and will refine the focus and enhance the intensity of our educational activities by developing and delivering webinars, tutorials, and cross-Core workshops that provide in-depth training on high priority research targets. The Core will also engage affiliates with active or pending digital health projects to include additional research aims that address our new priorities. e.g., add common metrics of outcomes related to scaling, mechanisms of change, or transdiagnostic processes; include passive sensing assessment to collect digital phenotyping data that may relate to substance use or relapse; and assess CODs in SUD projects to evaluate how they moderate intervention effects and how transdiagnostic interventions impact outcomes. These efforts will accelerate the state-of-the science of digital therapeutics for SUDs and related conditions across diverse populations.